Teva stock forecast 2025 market models for "Teva stock forecast

Market models for "Teva stock forecast 2025" highlight potential EPS acceleration by 8–12%, tied to robust pipeline developments in neurology and oncology. This aligns with historical sector performance, where regulated drug markets offer defensive growth during economic uncertainty. Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Teva Pharmaceutical Industries for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Recently Read Unlocking enterprise transformation: Why Israeli startups are poised to reshape insurance and finance AI did not generate this title $82B and counting: A new generation of Israeli cyber exits Forward-looking models for "Teva stock forecast 2025" assume continued trend of year-over-year revenue climb. Historical regression analysis of price versus earnings growth suggests price elasticity could yield double-digit return potential if 2024 trends hold.